On August 20, 2008, Dr. Eliot Phillipson, President and CEO of the Canada Foundation for Innovation (CFI) announced the investment of $119.9M towards UHN's Advanced Therapeutics Research Platform.

The award--the largest in UHN's history--includes $92.3M in new funding towards construction projects at Venus/TWRI, OCI and TGRI. It will fund significant new equipment across the seven research themes including signaling, clinical studies, stem cells, medical imaging, immunity, biomarkers and drug discovery programs.

"This is fantastic news for all of UHN," says UHN CEO Dr. Bob Bell. "This new investment by CFI will provide a further important boost to UHN's global impact. It will allow our research community to establish critical new resources that will transform healthcare for our patients, our community and the world."

"The award is a tribute to the internationally recognized strength of UHN's researchers and research programs," notes Dr. Christopher Paige, VP Research, UHN. "It represents a unique opportunity to create pioneering research platforms
integrated across UHN's labs and clinics. On behalf of UHN I offer our thanks to the researchers and staff who developed the winning proposal."

In addition, CFI announced a contribution of $27.6M in institutional operating funding related to the award.

For more information please visit innovation.ca or the Globe & Mail article